ArticleNeurology and therapy2026
A Collaborative Approach to Creating Knowledge-Building Resources for the Early-Stage Parkinson's Disease Community.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionParkinson's disease is a progressive neurodegenerative condition; there are no treatments currently available to slow disease progression, and no cure. Scientists are studying new treatments, such as disease-modifying therapies (DMTs), that may help slow progression of Parkinson's. Here, we discuss our approach to initiating a collaboration between industry and the Parkinson's community that explores the needs of people with early-stage Parkinson's and their care partners. The aim was to examine ways to build knowledge for newly diagnosed patients, align on the potential of DMTs and support discussions around any future clinical trial participation.
methodsAn exploratory workshop with patient advisors, patient advocacy groups (PAGs), and industry representatives was conducted to evaluate perceptions and identify challenges related to understanding disease modification in early-stage Parkinson's, including the development of a preliminary DMT narrative. Patients and care partners also completed a DMT perceptions questionnaire and tested the narrative for readability. A Strategic Patient Council (SPC) then guided refinement of the narrative and co-created a knowledge-building guide for the Parkinson's community.
resultsA total of 181 people with Parkinson's and their care partners completed the questionnaire. Of these, 72% strongly agreed on the need for new Parkinson's treatments, yet 59% felt that they lacked sufficient knowledge around symptom progression. Based on these data and feedback from the SPC, which comprised nine people from five PAGs, the DMT narrative was revised, leading to improved health literacy from 40% to 61%, within the 'adequate' range of the Suitability Assessment of Materials tool. The knowledge-building guide, informed by SPC input, incorporated a patient-centric framework and described key elements of living with early-stage Parkinson's, ranging from coping with diagnosis to clinical trial involvement.
conclusionA collaboration between industry and the Parkinson's community enabled successful development of knowledge-building materials tailored for people living with early-stage Parkinson's, empowering them with a clearer understanding of emerging innovative therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.